false 0001580149 0001580149 2024-07-25 2024-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 25, 2024

 

BioVie Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39015   46-2510769
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

680 W Nye Lane Suite 201

Carson City, NV

  89703
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (775) 888-3162

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 Per Share BIVI The Nasdaq Stock Market, LLC

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
   

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 25, 2024, Steve Gorlin notified the Board of Directors (the “Board”) of BioVie Inc. (the “Company”) of his intention to resign as a director of the Company, effective immediately. Mr. Gorlin’s resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company’s operations, policies or practices. The Company expresses its gratitude to Mr. Gorlin for his service and contributions during his tenure on the Board.

 

 -1- 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BioVie INC.
     
  By: /s/ Joanne Wendy Kim
    Name: Joanne Wendy Kim
    Title: Chief Financial Officer
       
Date: July 30, 2024      

 

 -2- 

 

 

v3.24.2
Cover
Jul. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 25, 2024
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 Per Share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

BioVie (NASDAQ:BIVI)
過去 株価チャート
から 7 2024 まで 7 2024 BioVieのチャートをもっと見るにはこちらをクリック
BioVie (NASDAQ:BIVI)
過去 株価チャート
から 7 2023 まで 7 2024 BioVieのチャートをもっと見るにはこちらをクリック